$EXAM (ExamWorks Group, Inc.)

$EXAM {{ '2016-04-27T18:57:22+0000' | timeago}} • Announcement

$EXAM said it agreed to be acquired by an affiliate of Leonard Green & Partners, L.P. for $35.05 per share in cash, representing a total value of approx. $2.2Bil. The offer price represents a 22% premium to the 90-day volume weighted average closing price of the company's shares as of April 26, 2016. The deal is currently expected to close in 3Q16.

$ABBV {{ '2017-07-28T15:50:59+0000' | timeago}} • Infographic

$ABBV AbbVie, Inc. Earnings AlphaGraphics: Q2 2017 highlights

$EBS {{ '2017-07-28T14:11:37+0000' | timeago}} • Announcement

$EBS and Valneva plan to initiate the Phase 1 trial in late 2017 or early 2018 and will share all costs until the availability of Phase 1 data, which is expected within six months from trial initiation. $EBS will have option to continue development arrangement with Valneva for milestone payment of EUR5MM, upon availability of Phase 1 data.

$EBS {{ '2017-07-28T14:10:27+0000' | timeago}} • Announcement

$EBS will pay Valneva EUR1MM upfront and will get exclusive rights to use Valneva’s intellectual property and know-how related to Zika product development. The companies are expected to enter into a technology transfer agreement at a later time to enable transfer of Valneva's technology to $EBS' Bayview manufacturing facility in Baltimore, MD.

$EBS {{ '2017-07-28T13:58:39+0000' | timeago}} • Announcement

$EBS announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's Zika vaccine technology, ZIKV. Emergent and Valneva will co-develop ZIKV-VLA1601, a highly purified inactivated vaccine candidate against Zika virus, from preclinical development through completion of a Phase 1 safety and immunogenicity clinical trial.

$ABBV {{ '2017-07-28T12:13:15+0000' | timeago}} • Announcement

Global HUMIRA sales for $ABBV rose 13.7% in 2Q17, while Global IMBRUVICA net revenues jumped 42.6%. The gross margin ratio in the second quarter was 78.0%, with adjusted gross margin ratio at 82.3%.

$ABBV {{ '2017-07-28T12:04:31+0000' | timeago}} • Announcement

While posting 2Q17 results, $ABBV confirmed its GAAP diluted EPS guidance for FY17 of $4.55-4.65. AbbVie expects to deliver adjusted diluted EPS of $5.44 to $5.54, representing growth of 13.% at the mid-point.

$ABBV {{ '2017-07-28T12:02:43+0000' | timeago}} • Announcement

With the biopharma giant's net revenues up 7.6% to $6.9Bil in 2Q17, $ABBV's net earnings soared 19% to $1.9Bil or $1.19 per share.  Adjusted diluted EPS was $1.42, up 12.7% in the quarter.

$ABBV {{ '2017-07-21T16:09:32+0000' | timeago}} • Announcement

$ABBV received positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for Humira (adalimumab) for the treatment of chronic non-infectious anterior uveitis in pediatric patients. Uveitis is an inflammation of the uvea, which includes the iris, choroid, and the ciliary body in eye.

$PRGO {{ '2017-07-17T13:30:02+0000' | timeago}} • Announcement

$PRGO received final approval from the FDA for its AB rated Abbreviated New Drug Application referencing $ABBV's Androgel Topical Gel, 1.62% packets. The gel is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

$EBS {{ '2017-07-14T12:28:37+0000' | timeago}} • Announcement

$EBS has entered into an agreement to acquire the ACAM2000 business of Sanofi in an all-cash transaction with a total value of $125MM. The transaction, which is subject to customary closing conditions including antitrust regulatory approval, is expected to close in 2017.

$PRSC {{ '2017-07-07T15:47:58+0000' | timeago}} • Announcement

$PRSC has appointed Jeff Felton as the CEO of its subsidiary LogistiCare Solutions, LLC, effective July 10, 2017. He most recently served as President of McKesson Connected Care and Analytics and he has also worked at Cardinal Health, Baxter Healthcare and Procter and Gamble.

$USPH {{ '2017-06-29T19:00:45+0000' | timeago}} • Webcast

$USPH estimates its corporate office costs, as a percentage of revenue, will be in the upper 8% to lower 9% range this year. The company said its recently adopted accounting standard and a change in the value of restricted share grants resulted in tax credit in 1Q17. The current focus is on acquisition-related opportunities to sustain growth.

$USPH {{ '2017-06-29T18:56:30+0000' | timeago}} • Webcast

$USPH expects its newly-launched analytics tool to bear good fruit as the year progresses. The company intends to continue consolidation of its smaller partnerships. The visits per clinic per day progressed sequentially in 1Q17 and has continued to progress well.

$WBA {{ '2017-06-29T14:01:47+0000' | timeago}} • Announcement

$WBA agreed to buy 2,186 stores, three distribution centers and related inventory from $RAD. $WBA expects the new transaction to be modestly accretive to its adjusted EPS in the first full year after the initial closing of the new transaction, and expects to realize synergies from the new transaction in excess of $400MM.

$WBA {{ '2017-06-29T14:01:00+0000' | timeago}} • Announcement

$WBA agreed to buy 2,186 stores, three distribution centers and related inventory from $RAD. This new agreement replaces the previous merger agreement with Rite Aid, announced in October 2015 and amended in January 2017. The initial closing of the new transaction is expected to occur within the next six months.

$WBA {{ '2017-06-29T14:00:00+0000' | timeago}} • Announcement

$WBA agreed to buy 2,186 stores, three distribution centers and related inventory from $RAD. The consideration for the transaction will be $5.175Bil in cash, the assumption by $WBA of the related real estate leases and the grant of an option to $RAD to become a member of $WBA's group purchasing organization, Walgreens Boots Alliance Development.

$WBA {{ '2017-06-29T13:35:36+0000' | timeago}} • Webcast

$WBA said that on the $RAD agreement, while the company is assuming a real-estate obligation, it is not assuming any debt. Additionally, $WBA is expecting the deal to give significant cash tax benefit, as it tax amortizes the intangible assets it acquires from $RAD.

$USPH {{ '2017-06-29T12:50:35+0000' | timeago}} • Announcement

$USPH's revenue for 1Q17 increased 12.3% from last year. This was primarily due to a 10.1% rise in net patient revenues from physical therapy operations, higher revenues from management contracts due to rise in managed facilities and one month of revenues from workforce performance solutions business acquired in March 2017.

$USPH {{ '2017-06-29T12:48:56+0000' | timeago}} • Announcement

$USPH reported a rise in 1Q17 earnings as a rise in net patient revenues from physical therapy operations and an increase in revenues from management contracts drove revenue higher. Net income rose to $4.82MM or $0.38 per share from $4.49MM or $0.36 per share last year. Revenue grew 12.3% to $97.57MM. Operating EPS increased 8.5% to $0.51.

$RAD {{ '2017-06-29T12:19:47+0000' | timeago}} • Announcement

In 1Q18, $RAD opened one store, relocated four, remodeled 67 and expanded one store, bringing the total number of wellness stores chainwide to 2,482. The company closed 14 stores, resulting in a total store count of 4,523 at the end of the first quarter.

Recent Transcripts

CHE (Chemed Corp.)
Wednesday, July 26 2017 - 2:00pm
PETS (PetMed Express, Inc.)
Monday, July 24 2017 - 12:30pm
USPH (US Physical Therapy Inc.)
Thursday, June 29 2017 - 2:30pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
PMC (PharMerica Corporation)
Wednesday, May 10 2017 - 2:00pm
PRSC (Providence Service Corp.)
Wednesday, May 10 2017 - 12:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
PETS (PetMed Express, Inc.)
Monday, May 8 2017 - 12:30pm
EBS (Emergent BioSolutions, Inc.)
Thursday, May 4 2017 - 9:00pm
LHCG (LHC Group, Inc.)
Thursday, May 4 2017 - 3:00pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
CVS (CVS Health Corporation)
Tuesday, May 2 2017 - 12:30pm
CHE (Chemed Corp.)
Thursday, April 27 2017 - 2:00pm
ABBV (AbbVie Inc.)
Thursday, April 27 2017 - 1:00pm
VRML (Vermillion, Inc.)
Wednesday, March 29 2017 - 8:30pm
USPH (US Physical Therapy Inc.)
Thursday, March 16 2017 - 2:30pm
ATRS (Antares Pharma Inc.)
Tuesday, March 14 2017 - 12:30pm
PRSC (Providence Service Corp.)
Friday, March 10 2017 - 1:00pm

AlphaGraphics you may like